Durable Complete Remission of a Brainstem Glioma Treated with a Combination of Bevacizumab and Cetuximab

被引：10

作者：

Gasent Blesa, Joan Manel ^{[1
]}

Blasco Molla, Sara ^{[1
]}

Fonfria Esparcia, Maria ^{[1
]}

Sempere Ortells, Jose Miguel ^{[5
]}

Peris Godoy, Miguel ^{[2
]}

Munilla Das, Adrian ^{[4
]}

Mancheno Magan, Balbino ^{[6
]}

Provencio Pulla, Mariano ^{[7
]}

Luis Sanchez, Jose ^{[8
]}

Laforga Canales, Juan Bautista ^{[3
]}

Alberola Candel, Vicente

机构：

[1] Hosp Denia, Dept Med Oncol, Marina Salud, Denia, Spain

[2] Hosp Denia, Dept Internal Med, Marina Salud, Denia, Spain

[3] Hosp Denia, Dept Pathol, Marina Salud, Denia, Spain

[4] Hosp Denia, Dept Pharm, Marina Salud, Denia, Spain

[5] Univ Alacant, Dept Immunol, Alacant, Spain

[6] Univ Alacant, Organ Chem, Alacant, Spain

[7] Hosp Puerta Hierro, Dept Med Oncol, Madrid, Spain

[8] Univ Catolic Valencia, Dept Eth, Valencia, Spain

来源：

CASE REPORTS IN ONCOLOGY | 2012年 / 5卷 / 03期

关键词：

Glioma; Durable remission; Bevacizumab; Cetuximab;

D O I：

10.1159/000341852

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Treatment of a relapsed glioma is a clinical challenge nowadays. New active treatments are required to treat these difficult diseases. Here we present a durable complete remission of a relapsed glioblastoma that has achieved a complete radiologic response with the combination of cetuximab and bevacizumab, in a third-line setting, that has offered a progression-free survival of 20 months. We consider here both potential mechanisms for the explanation of this result. First, the potential target of the cancer stem cells (CSCs) with these two antibodies, and second, the potential recruitment of the immune system to directly pursue the CSCs.

引用

页码：676 / 681

页数：6

共 21 条

[1] Prospective identification of tumorigenic breast cancer cells [J].

Al-Hajj, M ;

Wicha, MS ;

Benito-Hernandez, A ;

Morrison, SJ ;

Clarke, MF .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (07) :3983-3988

[2] Contemporary chemotherapy issues for children with brainstem gliomas [J].

Allen, JC ;

Siffert, J .

PEDIATRIC NEUROSURGERY, 1996, 24 (02) :98-102

[3] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[4] Lack of expression of Thy-1 (CD90) on acute myeloid leukemia cells with long-term proliferative ability in vitro and in vivo [J].

Blair, A ;

Hogge, DE ;

Ailles, LE ;

Lansdorp, PM ;

Sutherland, HJ .

BLOOD, 1997, 89 (09) :3104-3112

[5] Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].

Bonnet, D ;

Dick, JE .

NATURE MEDICINE, 1997, 3 (07) :730-737

[6] High-dose carmustine for high-grade gliomas in childhood [J].

Bouffet, E ;

Khelfaoui, F ;

Philip, I ;

Biron, P ;

BrunatMentigny, M ;

Philip, T .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1997, 39 (04) :376-379

[7]

Cloughesy T, 2008, P AN M AM SOC CLIN, V26, P2010

[8] Tumour stem cells and drug resistance [J].

Dean, M ;

Fojo, T ;

Bates, S .

NATURE REVIEWS CANCER, 2005, 5 (04) :275-284

[9] Chemotherapy for brain stem gliomas [J].

Freeman, CR ;

Perilongo, G .

CHILDS NERVOUS SYSTEM, 1999, 15 (10) :545-553

[10] Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma [J].

Galli, R ;

Binda, E ;

Orfanelli, U ;

Cipelletti, B ;

Gritti, A ;

De Vitis, S ;

Fiocco, R ;

Foroni, C ;

Dimeco, F ;

Vescovi, A .

CANCER RESEARCH, 2004, 64 (19) :7011-7021

← 1 2 3 →